- Home
- OPCH vs PBLS Comparison
OPCH vs PBLS Comparison
Compare OPCH & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | PBLS |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | OPCH | PBLS |
|---|---|---|
| Price | $21.73 | $31.63 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $36.57 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 451.4K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $4,998,202,000.00 | N/A |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | $75.21 | ★ N/A |
| Revenue Growth | ★ 16.17 | N/A |
| 52 Week Low | $18.01 | $25.56 |
| 52 Week High | $36.80 | $33.65 |
Technical Indicators
Market Signals| Indicator | OPCH | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 57.89 |
| Support Level | $20.82 | $26.83 |
| Resistance Level | $22.43 | $33.65 |
| Average True Range (ATR) | 0.59 | 2.51 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 61.62 | 69.57 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About PBLS Parabilis Medicines Inc. Common Stock
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.